Provided by Tiger Fintech (Singapore) Pte. Ltd.

Viking Therapeutics

32.10
+0.16000.50%
Post-market: 32.300.2000+0.62%19:59 EDT
Volume:2.81M
Turnover:90.00M
Market Cap:3.61B
PE:-27.83
High:32.59
Open:32.10
Low:31.63
Close:31.94
Loading ...

Viking Therapeutics rumor highlighted in Betaville alert

TIPRANKS
·
22 Feb

Why Viking Therapeutics, Inc. (VKTX) Went Up On Wednesday?

Insider Monkey
·
20 Feb

LLY Rises More Than 4% in a Week: How to Play the Stock

Zacks
·
13 Feb

Scotiabank Initiates Viking Therapeutics at Sector Outperform

MT Newswires Live
·
13 Feb

Viking Therapeutics Inc : Scotiabank Initiates Coverage With Sector Outperform Rating; Target Price $102

THOMSON REUTERS
·
13 Feb

Viking Therapeutics Initiated at Sector Outperform by Scotiabank

Dow Jones
·
13 Feb

Why Viking Therapeutics Inc. (VKTX) Went Down on Monday

Insider Monkey
·
11 Feb

Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today

Motley Fool
·
11 Feb

The M&A Boom Of 2025 Is Just Getting Started - And Here Are 5 Potential Targets

Dow Jones
·
09 Feb

Viking Therapeutics price target lowered to $96 from $109 at B. Riley

TipRanks
·
08 Feb

Down 65%, Is Viking Therapeutics Stock a Buy on the Dip?

Motley Fool
·
08 Feb

Viking Therapeutics price target lowered to $95 from $120 at Truist

TIPRANKS
·
08 Feb

Truist Securities Adjusts Viking Therapeutics Price Target to $95 From $120, Maintains Buy Rating

MT Newswires Live
·
07 Feb

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

Dow Jones
·
07 Feb

U.S. RESEARCH ROUNDUP-Altus Power, Amazon, Nevro

Reuters
·
07 Feb

Viking Therapeutics Reports Strong Trials and Financial Health

TIPRANKS
·
07 Feb

Viking Therapeutics Is Maintained at Strong Buy by Raymond James

Dow Jones
·
07 Feb

Viking Therapeutics Reports Q4 2024 Financial Results, Advances VK2735 Trials

GuruFocus.com
·
07 Feb

Stock Track | Viking Therapeutics Plunges Nearly 10% on Q4 Earnings Miss, Lack of Major Obesity Drug Updates

Stock Track
·
06 Feb

Stock Track | Viking Therapeutics Plunges Nearly 10% on Q4 Miss, Lack of Major Pipeline Breakthroughs

Stock Track
·
06 Feb